ESR2 and prostate carcinoma: Other investigators, using human cell lines derived from prostate cancer [68], gliomas [69] as well as T- and B-cell lymphomas [70], all of which expressed detectable levels of ERβ, found that treatment with ERβ specific agonists inhibited cell proliferation in vitro as well as growth and metastatic spread in xenograft in vivo models.